DHVI Mission:
The Duke Human Vaccine Institute will develop innovative diagnostics, vaccines  and therapeutics to prevent and treat diseases of global importance, work to implement them to eliminate health disparities, and train the next generation of scientists.

The Duke Human Vaccine Institute (DHVI) has established a place of national and international leadership in the fight against major infectious diseases. DHVI plays an integral leadership role in the Global HIV/AIDS Vaccine Enterprise and is a pioneer in emerging infections and biodefense research. By focusing on the scientific “bottlenecks” for the development of HIV, TB, and other vaccines, DHVI investigators continue to make significant contributions to overcome global health challenges on behalf of society. More

Press Releases

Scanning electron micrograph of HIV particles infecting a human H9 T cell, colorized in blue, turqoise, and yellow. Credit: NIAID

Duke VTEU Names Valley Fever External Advisory Panel
Duke News and Communications
October 27, 2015 

Immune Responses Provide Clues for HIV Vaccine Development
National Institute of Allergy and Infectious Diseases
October 21, 2015

Monkey Model Discovery Could Spur CMV Vaccine Development
Duke News and Communications
October 19, 2015 

Video Presentations

Dr. Sallie Permar Says Zika is Unusual for Mother-to-Child Transmission 
January 28, 2016
Sallie Permar, MD, PhD, directs the Laboratory of Neonatal Viral Pathogen Immunity at the DHVI. A pediatrician, Permar is also associate professor of immunology and of molecular genetics and microbiology at Duke.